New findings published in Nature Chemical Biology show promise for finding new solutions to treat lung cancer and other deadly diseases. Kentucky continues to lead the nation in incidence and death rates from lung cancer, and the University of Kentucky is committed to reducing these numbers.
According to the National Cancer Institute, cancer is among the leading causes of death worldwide. And of those diagnosed in the United States, lung cancer accounts for 25 percent of cancer deaths. The numbers are sobering: one out of every two patients diagnosed with lung cancer won’t survive past 12 months.
In an effort to combat this problem, a collaboration between scientists from University of Kentucky College of Pharmacy, Memorial Sloan Kettering Cancer Center, and St. Jude Children’s Research Hospital brings researchers one step closer to a solution.
A compound developed by Dean Kip Guy’s lab of UK College of Pharmacy, with research that began at St. Jude Children’s Research Hospital, now provides us with a way to block cancer-causing proteins on a cellular level.
The groundwork began more than 10 years ago when Dr. Bhuvanesh Singh, a physician-scientist at Memorial Sloan Kettering Cancer Center, identified that an increase of a protein called DCN1 led to more malignant lung cancers and shorter life spans for his patients. Of the patients he studied, those with high levels of DCN1 succumbed to the disease more quickly than those with normal levels.
Frustrated by their findings, Singh’s team set out to study the specifics of DCN1. While DCN1 is a normally occurring protein, his team found that too much of it leads directly to cancer formation. Simply put, a malignant tumor was formed when the amount of DCN1 in a cell was increased. Thus, patients with more DCN1 got sick more quickly and died faster than their counterparts.
Efforts in Brenda Schulman’s lab at St. Jude, led by biochemist Daniel Scott, established how DCN1 interacts with other proteins and controls cellular processes. Their key discovery used X-ray crystallography to show that a small modification of the partner protein to DCN1, known as UBE2M was required for DCN1 to work. This modification, N-terminal acetylation (while common) had not previously been shown to be critical to controlling activity of this specific protein. Recognizing the potential for targeting this modification, Schulman reached out to form a collaboration between the three laboratories.
Their goal: to develop a way to stop DCN1 from killing patients.
Understanding the behavior and function of DCN1 was far more ambitious than running simple tests. It was a significant step forward in understanding how proteins within a cell work.
Building upon the science from Schulman’s team, Jared Hammill from Guy’s lab and Danny Scott from Schulman’s lab worked to stop the interactions of DCN1 all together. If DCN1’s activity depended on this interaction, then it stood to reason they could create a compound to intervene and stop the interaction from happening.
Guy describes the interaction as a “lock and key model.” Scientists have a blank key—which is UBE2M—and a lock, which is DCN1. The key wants to fit into the lock so it’s modified until it fits. This modification process is N-terminal acetylation.
“What’s the significance?” Guy said. “Well, we’re the first people to show that protein interaction controlled by N-terminal acetylation can be blocked. We’re essentially jamming the lock with a compound so the key won’t fit.”
The items jamming that lock are a series of small molecules created in the lab. When the molecules were tested directly in cancer cells, they worked. They effectively blocked DCN1 from binding to UB2EM. After decades of collaborative research, there was finally a barrier between lock and key.
The impact of these findings for healthcare and lung cancer patients specifically could be profound.
“We are excited about the implications of this research, which offer us a meaningful solution for addressing diseases like cancer, neurodegenerative disorders, and infection,” Schulman said. “It’s exciting to collaborate with so many complementary groups of expertise and to watch how Dr. Scott and Dr. Hammill led the team. This research opens many new doors for us.”
The collaboration between these three labs could mean relief to many of those suffering from a variety of diseases.
“To have spent decades on this research and have such promising results is truly exhilarating,” Singh said. “At the end of the day, what matters most is improving health outcomes for our patients. This work represents a very important step towards developing a new approach to treat the most difficult of cancers and hopefully increase cure rates.”
The Latest on: Block cancer
Hingham, Silver Lake team up vs. cancer
on January 18, 2019 at 6:47 pm
Cancer games where every point scored by each team raised money ... loss while Hingham’s John Lowther led all scorers with 24 to go with 10 rebounds and four blocks. “That was the most physical game t... […]
AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study
on January 18, 2019 at 4:23 pm
Imbruvica, jointly sold with Johnson and Johnson, is an oral drug designed to target an enzyme known as Bruton’s tyrosine kinase and block the function of certain cancerous cells. The drug improved su... […]
Dr. John Mendelsohn, 82, Researcher Who Led Top Cancer Center, Dies
on January 18, 2019 at 8:44 am
He made his name in the 1980s at the University of California, San Diego, where he developed cetuximab, the first so-called targeted cancer therapy, which blocks receptors on cancer cells to halt thei... […]
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
on January 18, 2019 at 7:46 am
A Boston startup hoping to block cancer cells' ability to ward off the body's immune system just signed its second major pharmaceutical deal, announcing an $80 million partnership Friday to develop tw... […]
Block & Leviton LLP Reminds Shareholders of Securities Class Action Against Immunomedics; Investors Are Encouraged to Contact the Firm
on January 18, 2019 at 6:23 am
BOSTON, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP ... On January 17, 2019, the FDA rejected Immunomedics’ breast cancer drug application due to these unresolved manufacturing ... […]
Gene therapy blocks peripheral nerve damage in mice
on January 17, 2019 at 2:44 am
Peripheral neuropathy can result from chemotherapy for cancer treatment or poorly controlled ... but we currently don't have therapies that can directly block this process. For many neuropathies ... […]
Janssen gets EC nod for prostate cancer drug Erleada
on January 16, 2019 at 11:31 pm
Apalutamide holds capacity to block the androgen signaling pathway in prostate cancer cell. Apalutamide can restrict the growth of cancer cells in three ways, including preventing the binding of andro... […]
The 5 Main Lung Cancer Treatment Types
on January 15, 2019 at 1:08 pm
The antibodies target and block the interaction between the cancer cells and the immune cells that allows the cancer to “hide” from the immune response. “So by blocking that immune checkpoint, the imm... […]
Newly Discovered Mechanism Helps Our Own Immune Systems Fight Cancer
on January 14, 2019 at 5:50 pm
According to researchers, most patients with cancer either do not respond to immune checkpoint blockade (a type of drug that blocks certain proteins made by some types of immune system cells, such as ... […]
on January 14, 2019 at 1:31 pm
Some or all these symptoms may occur when a tumor blocks or slows the regular digestive processes. Weight loss can be caused by incomplete digestion due to the cancer or by the cancer itself. […]
via Google News and Bing News